Secondary prevention of fragility fractures: Are we following the guidelines? Closing the audit loop

Annals of the Royal College of Surgeons of England

Volumn 88, Issue 5, 2006, Pages 470-474

  Prasad, N ^a   Sunderamoorthy, D ^a   Martin, J ^a   Murray, J M ^a  

^a ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

Author keywords

Guidelines; Osteoporosis; Secondary prevention

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D;

ADULT; AGED; ARTICLE; AWARENESS; BLOOD CELL COUNT; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK FRACTURE; FRAGILITY FRACTURE; HUMAN; KIDNEY FUNCTION TEST; MEDICAL AUDIT; MENTAL HEALTH; NURSE PRACTITIONER; ORTHOPEDIC SURGERY; OSTEOPOROSIS; PATIENT REFERRAL; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; SURGEON; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; BONE DENSITY; FEMORAL NECK FRACTURES; FRACTURES, SPONTANEOUS; GUIDELINE ADHERENCE; HUMANS; MEDICAL AUDIT; MIDDLE AGED; ORTHOPEDICS; OSTEOPOROSIS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 33748677915     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588406X116891     Document Type: Article

References (21)

1. National Osteoporosis Society. .
2. The Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. London: RCP, 2001.
3. British Orthopaedic Association. The care of fragility fracture patients. London: BOA, 2003.
4. Khaw KT. How many, how old, how Soon? BMJ 1999; 319: 1350-2.
5. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Patterson C et al. Fracture risk following an osteoporotic fracture. Osteoporos Int 2004; 15: 175-9.
6. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-3.
7. Scottish Inter-Collegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. SIGN publication No 71. London: SIGN, 2003.
8. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8: 611-7.
9. Gullberg B, Johnell O, Kanis JA. Worldwide projections for hip fracture. Osteoporos Int 1997; 7: 407-13.
10. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. and The Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
11. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. and Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333-40.
12. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al. and Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with post-menopausal osteoporosis: a randomized controlled trial. JAMA 1999; 282: 1344-52.
13. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al. and Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83-91.
14. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Technical Report Series, No. 84. Geneva: WHO, 1994.
15. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001; 12: 989-95.
16. Brown MA, Bradlo N. Cost effectiveness of bone density measurement. J Br Menopause Soc 2001; 7: 130-5.
17. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis a systematic review and cost-utility analysis. Health Technol Assess 2002; 6: 1-146.
18. Smith MG, Dunkow P, Lang DM. Treatment of osteoporosis: missed opportunities in the hospital fracture clinic. Ann R Coll Surg Engl 2004; 86: 344-6.
19. Seagger R, Howell J, David H, Gregg-Smith S. Prevention of secondary osteoporotic fractures - Why are we ignoring the evidence? Injury 2004; 35: 986-8.
20. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fractures in post-menopausal women. NICE Technology Appraisal Guidance 87. London: NICE, 2005.
21. McLellan AR, Gallacher SJ, Fraser M, McQuillan C. The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 2003; 14: 1028-34.